Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | PRKCI | P41743 | 1/20 | 0.40 |
| ▸ | PRKCA | P17252 | 1/20 | 0.40 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | AGXT | P21549 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ACP3 | P15309 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6250682 | 0.83 | IDO1 (0.46) | SLC6A2SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL1680382 | 0.81 | HTR2C (0.61) | HTR2CHTR6PRKCISLC6A4DDB1 | |
| SCHEMBL11664820 | 0.79 | XBP1 (0.51) | HTR2CHTR6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4938425 | 0.78 | PRKCI (0.61) | HTR2CHTR6PRKCIDDB1CRBN | |
| SCHEMBL19116399 | 0.77 | HTR2C (0.45) | HTR2CHTR6PRKCISLC6A4DDB1 | |
| SCHEMBL9326494 | 0.76 | SLC6A2 (0.45) | HTR2CHTR6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2257 | 0.75 | TAAR1 (0.60) | HTR2CPRKCAPRKCDSLC6A4GRIN2B | |
| Hydrochloric Acid SCHEMBL9326715 | 0.75 | MEN1 (0.45) | HTR2CHTR6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL30542002 | 0.75 | AGXT (0.64) | PRKCIAGXT | |
| SCHEMBL2244213 | 0.75 | AGXT (0.64) | PRKCIAGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003648-B2 | Heterocyclic GPR40 modulators | AMGEN INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003648-B2 | Heterocyclic GPR40 modulators | AMGEN INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003648-B2 | Heterocyclic GPR40 modulators | AMGEN INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-7714008-B2 | Heterocyclic GPR40 modulators | AMGEN INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7714008-B2 | Heterocyclic GPR40 modulators | AMGEN INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7714008-B2 | Heterocyclic GPR40 modulators | AMGEN INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20100075974-A1 | HETEROCYCLIC GPR40 MODULATORS | AMGEN INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075974-A1 | HETEROCYCLIC GPR40 MODULATORS | AMGEN INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-20100075974-A1 | HETEROCYCLIC GPR40 MODULATORS | AMGEN INC. (US) | 2010-03-25 | — | — | US | disclosed |
| EP-2064193-A1 | HETEROCYCLIC GPR40 MODULATORS | Amgen, Inc (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20080090840-A1 | Heterocyclic GPR40 Modulators | AMGEN INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080090840-A1 | Heterocyclic GPR40 Modulators | AMGEN INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080090840-A1 | Heterocyclic GPR40 Modulators | AMGEN INC. (US) | 2008-04-17 | — | — | US | disclosed |
| WO-2008030520-A1 | HETEROCYCLIC GPR40 MODULATORS | AMGEN INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| WO-2008030520-A1 | HETEROCYCLIC GPR40 MODULATORS | AMGEN INC. (US) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075974-A1 | HETEROCYCLIC GPR40 MODULATORS | GPR119, GPR55, GPR65 | HTR2C 544/4885HTR6 278/4885PRKCI 1683/4885 |
| US-20080090840-A1 | Heterocyclic GPR40 Modulators | GPR119, GPR55, GPR65 | HTR2C 544/4885HTR6 278/4885PRKCI 1683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.